New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 20.8mg equivalent to rosuvastatin 20mg;   - film coated tablet - 20 mg - active: rosuvastatin calcium 20.8mg equivalent to rosuvastatin 20mg   excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate   magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 41.6mg equivalent to rosuvastatin 40mg;   - film coated tablet - 40 mg - active: rosuvastatin calcium 41.6mg equivalent to rosuvastatin 40mg   excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate   magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 5.2mg equivalent to rosuvastatin 5mg;   - film coated tablet - 5 mg - active: rosuvastatin calcium 5.2mg equivalent to rosuvastatin 5mg   excipient: calcium phosphate crospovidone hypromellose iron oxide yellow lactose monohydrate   magnesium stearate microcrystalline cellulose titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - dapoxetine hydrochloride 33.6mg equivalent to dapoxetine 30 mg;   - film coated tablet - 30 mg - active: dapoxetine hydrochloride 33.6mg equivalent to dapoxetine 30 mg   excipient: colloidal silicon dioxide croscarmellose sodium coating powder grey 4 lactose monohydrate as a spray-dried mixture of lactose monohydrate & microcrystalline cellulose magnesium stearate microcrystalline cellulose as a spray-dried mixture of lactose monohydrate & microcrystalline cellulose - priligy is indicated for the treatment of premature ejaculation (pe) in men 18 to 64 years of age, who have all of the following: · persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and · marked personal distress or interpersonal difficulty as a consequence of pe; and · poor control over ejaculation.

New Zealand - English - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - dapoxetine hydrochloride 67.2mg equivalent to dapoxetine 60 mg;   - film coated tablet - 60 mg - active: dapoxetine hydrochloride 67.2mg equivalent to dapoxetine 60 mg   excipient: colloidal silicon dioxide croscarmellose sodium coating powder grey 3 lactose monohydrate as a spray-ried mixture of lactose monohydrate & microcrystalline cellulose magnesium stearate microcrystalline cellulose as a spray-ried mixture of lactose monohydrate & microcrystalline cellulose - priligy is indicated for the treatment of premature ejaculation (pe) in men 18 to 64 years of age, who have all of the following: · persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and · marked personal distress or interpersonal difficulty as a consequence of pe; and · poor control over ejaculation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gabapentin, quantity: 400 mg - capsule - excipient ingredients: purified talc; lactose monohydrate; maize starch; iron oxide yellow; iron oxide red; titanium dioxide; gelatin; propylene glycol; indigo carmine; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution - gapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic medicines. gapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: maize starch; iron oxide yellow; titanium dioxide; purified talc; lactose monohydrate; gelatin; propylene glycol; indigo carmine; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution - gapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic medicines. gapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gabapentin, quantity: 100 mg - capsule - excipient ingredients: maize starch; gelatin; purified talc; lactose monohydrate; titanium dioxide; propylene glycol; indigo carmine; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution - gapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic medicines. gapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - omeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: purified talc; iron oxide black; iron oxide red; erythrosine; titanium dioxide; purified water; gelatin; hypromellose; methacrylic acid copolymer; dibasic sodium phosphate dihydrate; triethyl citrate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide - maxor heartburn relief is indicated for the symptomatic relief of heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - newcastle disease strain v-4 virus - unknown - newcastle disease strain v-4 virus vaccine-viral active 0.0 - active constituent